## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86020

Motonori MIYAKAWA, et al.

Appln. No.: 10/522,553

Group Art Unit: 1625

Confirmation No.: 8524

Examiner: Rita J DESAI

Filed: February 1, 2005

For: NOVEL TETRAHYDROQUINOLINE DERIVATIVES

## STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on July 22, 2008 and July 25, 2008:

## **REMARKS**

An Examiner's Interview Summary Record (PTO-413) was attached with the Advisory Action dated July 28, 2008.

The interview was initiated by the Examiner. Therefore, no further recordation by the Applicant is believed to be required.

During the interview, the following was discussed:

- 1. Brief description of exhibits or demonstration: None.
- 2. Identification of claims discussed: All.
- 3. Identification of art discussed: None.

STATEMENT OF SUBSTANCE OF INTERVIEW

U.S. Application No.: 10/522,553

allegedly lack enablement.

4. Identification of principal proposed amendments: The Examiner stated that claims 1, 2, 6 and 9 were allowable, and requested that claims 10-16 be canceled, as they

Attorney Docket No.: Q86020

- 5. Brief Identification of principal arguments: Applicants' representative requested that claims 11 and 14 be re-joined and allowed in view of the data in test Examples 2 to 4 of the present application showing that the compounds of the invention have potent action on bone tissue and skeletal muscle tissue. Therefore preventing or treating the effects of osteoporosis or wasting disease were sufficiently enabled.
  - 6. Indication of other pertinent matters discussed: None.
- 7. Results of Interview: The Examiner refused to rejoin claims 11 and 14 and consider their patentability. Applicants' representative requested that an Advisory Action be issued.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

STATEMENT OF SUBSTANCE OF INTERVIEW

U.S. Application No.: 10/522,553

Attorney Docket No.: Q86020

It is believed that no petition or fee is required. However, if the USPTO deems

otherwise, Applicant hereby petitions for any extension of time which may be required to

maintain the pendency of this case, and any required fee, except for the Issue Fee, for such

extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 11, 2008

3